MedTrace Logo

A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.

NCT04855929 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2024-11-08

No results posted yet for this study

Summary

The purpose of this study is to test the safety and efficacy of ANV419 (single agent) and in combination with ipilimumab in patients with relapsed/refractory advanced solid tumors.

Conditions

Interventions

DRUG

ANV419

ANV419 administered by intravenous (IV) infusion

DRUG

Ipilimumab

Ipilimumab administered by intravenous (IV) infusion

Sponsors & Collaborators

  • Anaveon AG

    lead INDUSTRY

Principal Investigators

  • Eduard Gasal, MD · Anaveon AG

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-25
Primary Completion
2024-07-18
Completion
2024-07-18

Countries

  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04855929 on ClinicalTrials.gov